Effect of hypoxia and TGFβ1 on gene expression in HPF fibroblast cells
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA587746 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR10402078_1.fastq.gz | Fastqsanger.gz | |||
| SRR10402078_2.fastq.gz | Fastqsanger.gz | |||
| SRR10402079_1.fastq.gz | Fastqsanger.gz | |||
| SRR10402079_2.fastq.gz | Fastqsanger.gz | |||
| SRR10402080_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 24 |
Similar Datasets
Project description:We performed RNA sequencing to reveal genome-wide changes of genes in hypoxia and/or TGFβ1-treated human lung fibroblasts
2019-11-06 | GSE139963 | GEO
Project description:4 replicates were prepared from A2058 melanoma cells [transfected with 10ng of empty vector (pcDNA3.1+)] and treated with 5ng/ml TGFβ1 or vehicle control for 24hrs This is the control arm of a larger experiment where cells transfected with a particular expression plasmid were treated with TGFβ1 or control vehicle. The transfection with the expresion plasmid was unsucessful so this empty vector data has been used alone to simply examine the effect of TGFβ1 treatment on A2058 cells.
2015-02-20 | E-GEOD-66114 | biostudies-arrayexpress
Project description:Pulmonary fibrosis is a progressive interstitial lung disease characterized by excessive fibroblast-to-myofibroblast transition (FMT) and extracellular matrix (ECM) deposition, largely driven by transforming growth factor-beta 1 (TGFβ1). Existing therapies offer limited efficacy, particularly in advanced disease. Circadian rhythms have recently emerged as key modulators of lung inflammation and fibrosis. In this study, we developed an in vitro model of chronic fibrotic signaling using adenovirus-mediated TGFβ1 overexpression (Ad-TGFβ1) or human recombinant protein TGFβ1 in primary human lung fibroblasts. Using this model, we investigated the antifibrotic potential of STL1267, a next-generation Rev-erbα agonist with improved potency, specificity, and pharmacokinetic properties. RNA sequencing and pathway analysis revealed that STL1267 significantly reversed Ad-TGFβ1-induced expression of genes associated with ECM remodeling, collagen biosynthesis, and immune suppression. STL1267 also upregulated pathways related to IL-10, IL-4, and IL-13 signaling, which are known to counteract fibrotic responses. Quantitative PCR and immunoblotting confirmed STL1267's ability to downregulate key pro-fibrotic markers, including COL1A1, αSMA, FN1, and FAP, at both gene and protein levels. Comparative studies with other Rev-erbα agonists (GSK4112, SR9009), Saracatinib, and FDA-approved antifibrotic drugs (Pirfenidone, Nintedanib) demonstrated superior efficacy of STL1267 in inhibiting both preventive and post-fibrotic induction models. Moreover, lentiviral overexpression of Rev-erbα suppressed TGFβ1-induced αSMA expression, supporting a direct antifibrotic role. These findings highlight Rev-erbα as a key regulator of myofibroblast differentiation and support both STL1267 and GSK4112 as promising candidates for circadian-based antifibrotic therapy. Future in vivo studies are warranted to evaluate its translational potential in idiopathic pulmonary fibrosis.
2026-01-20 | GSE293962 | GEO
Project description:To further explore the effect of NAM on the TGFβ1-induced hESC-derived corneal endothelial progenitor cells, we have employed whole RNA microarray expression profiling as a discovery platform to identify genes and mechanism of NAM on the EnMT and senescence. hESC-derived endothelial progenotors were culured under 30ng/ml TGFβ1 with or without 50 mM NAM. The cultures were incubated for 72 hours at 37 ºC in a humidified incubator with 5% CO2.
2022-01-05 | GSE183786 | GEO
Project description:To investigate TGFβ1 (a key member of the TGFβ superfamily) signaling in non-cancerous and cancerous cells derived from breast epithelium and what further response it might generate, we treated the cells with TGFβ1 or with conditioned media. We selected MCF10A non-tumorigenic breast epithelial cells (isolated from the mammary gland with fibrocystic disease) and MCF7 breast adenocarcinoma cells (estrogen receptor-positive, ER+). We followed a regimen of treating the cells for six consecutive days, with daily administration of TGFβ1 for two hours. The TGFβ1-containing medium was changed to a fresh one, which was collected after another 22 hours (so-called conditioned medium, CM) and administered to other cells. This enabled us to assess the ability of extracellularly secreted molecules to further induce a cellular response (bystander effect). RNA-seq analyses were performed on cells either directly treated with TGFβ1 in the above scheme or treated with a conditioned media for 1, 2, 3, 4, 5, or 6 days. The experiment was performed in three biological replicates, and each sample was sequenced separately. RNA-seg analysis in both cell lines allowed us to find the differences and similarities in response to TGFβ1 and CM. All 84 libraries were sequenced on Illumina NovaSeq6000 platform, in 2x150 mode, with a coverage of 60M reads/sample.
2024-12-01 | E-MTAB-13865 | biostudies-arrayexpress
Project description:STL1267 Inhibits Myofibroblast Differentiation in a TGFβ1-Driven Human Lung Fibroblast Model
| PRJNA1247501 | ENA
Project description:Fibroblast activation drives tissue fibrosis and is often mediated by TGFβ1 signaling. Human fibroblasts were pre-treated with the NNMT inhibitor II559 for 12 hours, followed by TGFβ1 stimulation for 72 hours. Transcriptomic profiling revealed that II559 prevented pro-fibrotic gene expression, providing a resource for understanding how NNMT inhibition modulates fibroblast activation and fibrotic remodeling.
2026-01-22 | GSE317322 | GEO
Project description:Activation of fibroblasts and formation of myofibroblasts are essential for granulation tissue formation following injury. In fibrotic reactions, excessive deposition of ECM by the activated fibroblasts determines scar formation and functional failure. Although these events critically depend on the activity of a plethora of growth factors and cytokines, TGFβ1 is a unique player controlling the immune response and proliferation of many cell types. Different cell types contribute to its release and activation, which is also regulated by the interaction with the ECM and by mechanical forces. The aim of this study was to elaborate whether fibroblast-derived TGFβ1 plays a critical role during these processes. The data demonstrate a dynamic expression of TGFβ1 during tissue repair. Cell-specific ablation of Tgfb1 in fibroblasts revealed that deletion of TGFβ1 attenuates bleomycin-induced skin fibrosis and delays maturation of granulation tissue in skin wounds. Absence of fibroblast-derived TGFβ1 induced vascular alterations (less vascular density and branching, hemorrhage) in early wound healing, potentially influenced by coincident alterations in the formation of stable ECM structure. This can be explained by paracrine regulation of endothelial cells or pericytes by fibroblast-released TGFβ1 and by impaired expression of pro-angiogenic factors in TGFβ1-deficient fibroblasts. Our findings provide novel mechanistic insights into the central role of fibroblast-derived TGFβ1 for early stages of tissue repair and fibrosis in the skin.
2025-07-14 | GSE298182 | GEO
Project description:Fibrosis is an uncontrolled wound healing process resulting from tissue injury, inflammation and fibroblast activation, finally leading to accumulation of extracellular matrix (ECM) components in tissues and to organ failure. The underlying mechanisms of fibrosis have been intensely studied and it has become clear that multiple pathways and their crosstalk regulate fibrotic diseases with a few central players, including TGFβ1. Recently, YAP and TAZ were implicated in fibrosis as one of the essential components of its pathogenesis. YAP/TAZ are known to crosstalk with the TGFβ pathway in the nucleus and regulate its activity on transcriptional level by binding to Smad2/3/4 complexes. We hypothesized that factors, such as GPCR ligands which regulate YAP/TAZ, might modulate the profibrotic responses to TGFβ1. We performed gene expression microarray in NHDF treated with TGFβ1, LPA, the combination of TGFβ1/LPA or vehicle. The aim was to have a broader look at transcriptional signatures induced by the individual treatments and in the combination of TGFβ1 and LPA.
2020-01-27 | GSE125519 | GEO
Project description:Introduction: Preclinical models that are currently used for fibrosis research only partially mimic human disease processes. Particularly, traditional transforming growth factor beta 1 (TGFβ1) induced stellate cell models are lacking in activation of hypoxia-induced pathways, which is a relevant process in patients with liver disease. Here we investigated the synergic effect of two hypoxia-mimicking compounds (DMOG and IOX2) and TGFβ1, on fibrotic phenotype and in vivo disease recapitulation in primary human hepatic stellate cells (HSCs). Methods: Human primary HSCs were cultured, stimulated (TGFβ1 and hypoxia-mimicking compounds combinations) and harvested to identify optimal stimulation conditions for fibrotic phenotype, cell viability and toxicity levels. To assess the fibrotic phenotype, protein levels was assayed for fibrosis markers (collagen, TIMP-1, Fibronectin) were evaluated. RNA was isolated and sequenced through next generation sequencing (NGS). Bioinformatic tools using differential expression analysis (Deseq2) and Ingenuity Pathway Analysis (IPA) were used to identify differentially expressed genes (DEGs) and map these to biological functionality, respectively. Results: Our HSC model showed that stimulation with IOX2 (0.3 and 1 µM) in the presence of TGFβ1 significantly increased fibrotic markers levels (total collagen, TIMP-1, and fibronectin). DMOG showed no effect using low, non-toxic concentrations. Biological functionality from DEGs highlighted various fibrosis-related pathways, hypoxia-related genes and relevant crosslinking markers when IOX2 was added in a concentration-dependent manner. Furthermore, comparative analysis with human DEGs (Fibrotic vs non-fibrotic) showed improved disease representation in our HSC model with IOX2 addition. Conclusion: These findings suggest that IOX2 may aggravate fibrotic disease and improve in vivo disease recapitulation in vitro. Hypoxia-mimicking compounds like IOX2 hold promise for enhancing fibrosis in in vitro models, providing valuable insights into fibrosis pathogenesis, hypoxia-related genes and potential therapeutic strategies.
2025-07-02 | GSE278541 | GEO